Introduction: Central serous chorioretinopathy (CSCR) is characterized by macular serous retinal and/or retinal pigment epithelium (RPE) detachment. It is most common in men aged 30 to 50 years. Aims and objectives: The main objective of the study is to analyze the role of oral rimpampicin in chronic central serous chorioretinopathy.Material and methods: This observationalsectional study was conducted in Department of Ophthalmology, Independent Medical College, Faisalabadduring February 2018 to November 2018. The data were collected from seven patients with age range 30 to 50 years. The diagnosis of chronic CSCR was based on the presence of SRF >3 months duration with/without diffuse retinal pigment epithelial (DRPE) changes.Patients with evidence of serous elevations secondary to other ocular conditions such as optic disc pit, multifocal choroiditis, posterior scleritis, choroidal mass or associated systemic illnesses were excluded from the study. Results: The data were collected from seven patients with mean age range 35.22±5.22 years. Mean best corrected visual acuity (BCVA) was 0.56± 0.116 with a range of 0.00 to 0.77 before starting the treatment while after treatment at 04 weeks visual acuity was of 0.147± 0.148. The mean CMT at the time of presentation was 494.39±96.2 um while it was 306.90 after 04 weeks of starting half dose (300 mg daily) Rifampicin. The mean induced reduction in CMT was 187.48±122 um while that in BCVA was 0.41± 0.16. Conclusion: It is concluded that oral rifampicin to be an effective and affordable therapy for eyes with chronic CSCR. In eyes with extensive RPE damage, rifampicin is not very effective in causing resorption of SRF and improvement in vision.